skip to main content
Idioma:
Resultados 1 2 3 4 5 next page
Mostrar Somente
Refinado por: Base de dados/Biblioteca: Journals@Ovid Ovid Full Text remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes
Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes
Material Type:
Artigo 		Adicionar ao Meu Espaço

Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes

Cannon, Christopher P ; Pratley, Richard ; Dagogo-Jack, Samuel ; Mancuso, James ; Huyck, Susan ; Masiukiewicz, Urszula ; Charbonnel, Bernard ; Frederich, Robert ; Gallo, Silvina ; Cosentino, Francesco ; Shih, Weichung J ; Gantz, Ira ; Terra, Steven G ; Cherney, David Z.I ; McGuire, Darren K

The New England journal of medicine, 2020-10, Vol.383 (15), p.1425-1435 [Periódico revisado por pares]

Boston: Massachusetts Medical Society

Texto completo disponível

Citações Citado por
2
Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET)
Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET)
Material Type:
Artigo 		Adicionar ao Meu Espaço

Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET)

Rosenstock, Julio ; Frias, Juan ; Páll, Dénes ; Charbonnel, Bernard ; Pascu, Raluca ; Saur, Didier ; Darekar, Amanda ; Huyck, Susan ; Shi, Harry ; Lauring, Brett ; Terra, Steven G.

Diabetes, obesity & metabolism, 2018-03, Vol.20 (3), p.520-529

Oxford, UK: Blackwell Publishing Ltd

Texto completo disponível

Citações Citado por
3
Efficacy of Ertugliflozin on Heart Failure–Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial
Efficacy of Ertugliflozin on Heart Failure–Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Efficacy of Ertugliflozin on Heart Failure–Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial

Cosentino, Francesco ; Cannon, Christopher P ; Cherney, David Z.I ; Masiukiewicz, Urszula ; Pratley, Richard ; Dagogo-Jack, Sam ; Frederich, Robert ; Charbonnel, Bernard ; Mancuso, James ; Shih, Weichung J ; Terra, Steven G ; Cater, Nilo B ; Gantz, Ira ; McGuire, Darren K

Circulation (New York, N.Y.), 2020-12, Vol.142 (23), p.2205-2215 [Periódico revisado por pares]

Hagerstown, MD: by the American College of Cardiology Foundation and the American Heart Association, Inc

Texto completo disponível

Citações Citado por
4
Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV)
Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV)
Material Type:
Artigo 		Adicionar ao Meu Espaço

Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV)

Cannon, Christopher P. ; McGuire, Darren K. ; Pratley, Richard ; Dagogo-Jack, Sam ; Mancuso, James ; Huyck, Susan ; Charbonnel, Bernard ; Shih, Weichung J. ; Gallo, Silvina ; Masiukiewicz, Urszula ; Golm, Gregory ; Cosentino, Francesco ; Lauring, Brett ; Terra, Steven G.

The American heart journal, 2018-12, Vol.206, p.11-23 [Periódico revisado por pares]

United States: Elsevier Inc

Texto completo disponível

Citações Citado por
5
A population pharmacokinetic and pharmacokinetic‐pharmacodynamic analysis of vupanorsen from phase I and phase II studies
A population pharmacokinetic and pharmacokinetic‐pharmacodynamic analysis of vupanorsen from phase I and phase II studies
Material Type:
Artigo 		Adicionar ao Meu Espaço

A population pharmacokinetic and pharmacokinetic‐pharmacodynamic analysis of vupanorsen from phase I and phase II studies

Ahn, Jae Eun ; Terra, Steven G. ; Liu, Jing

CPT: pharmacometrics and systems pharmacology, 2023-07, Vol.12 (7), p.988-1000 [Periódico revisado por pares]

United States: John Wiley & Sons, Inc

Texto completo disponível

Citações Citado por
6
Long‐term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study
Long‐term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study
Material Type:
Artigo 		Adicionar ao Meu Espaço

Long‐term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study

Aronson, Ronnie ; Frias, Juan ; Goldman, Allison ; Darekar, Amanda ; Lauring, Brett ; Terra, Steven G.

Diabetes, obesity & metabolism, 2018-06, Vol.20 (6), p.1453-1460

Oxford, UK: Blackwell Publishing Ltd

Texto completo disponível

Citações Citado por
7
Type 2 Diabetes: Progress Made but Still a Long Road to Travel to Reduce Disease Burden
Type 2 Diabetes: Progress Made but Still a Long Road to Travel to Reduce Disease Burden
Material Type:
Artigo 		Adicionar ao Meu Espaço

Type 2 Diabetes: Progress Made but Still a Long Road to Travel to Reduce Disease Burden

Terra, SG ; Vincent, J

Clinical pharmacology and therapeutics, 2015-08, Vol.98 (2), p.108-111 [Periódico revisado por pares]

United States: Blackwell Publishing Ltd

Texto completo disponível

Citações Citado por
8
Long‐term efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: 104‐week VERTIS MET trial
Long‐term efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: 104‐week VERTIS MET trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Long‐term efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: 104‐week VERTIS MET trial

Gallo, Silvina ; Charbonnel, Bernard ; Goldman, Allison ; Shi, Harry ; Huyck, Susan ; Darekar, Amanda ; Lauring, Brett ; Terra, Steven G.

Diabetes, obesity & metabolism, 2019-04, Vol.21 (4), p.1027-1036

Oxford, UK: Blackwell Publishing Ltd

Texto completo disponível

Citações Citado por
9
Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone
Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone
Material Type:
Artigo 		Adicionar ao Meu Espaço

Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone

Terra, Steven G. ; Focht, Kristen ; Davies, Melanie ; Frias, Juan ; Derosa, Giuseppe ; Darekar, Amanda ; Golm, Gregory ; Johnson, Jeremy ; Saur, Didier ; Lauring, Brett ; Dagogo‐Jack, Sam

Diabetes, obesity & metabolism, 2017-05, Vol.19 (5), p.721-728

Oxford, UK: Blackwell Publishing Ltd

Texto completo disponível

Citações Citado por
10
Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial
Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial

Pratley, Richard E. ; Eldor, Roy ; Raji, Annaswamy ; Golm, Gregory ; Huyck, Susan B. ; Qiu, Yanping ; Sunga, Sheila ; Johnson, Jeremy ; Terra, Steven G. ; Mancuso, James P. ; Engel, Samuel S. ; Lauring, Brett

Diabetes, obesity & metabolism, 2018-05, Vol.20 (5), p.1111-1120

Oxford, UK: Blackwell Publishing Ltd

Texto completo disponível

Citações Citado por
Resultados 1 2 3 4 5 next page

Personalize Seus Resultados

  1. Editar

Refine Search Results

Expandir Meus Resultados

  1.   

Mostrar Somente

  1. Revistas revisadas por pares (220)

Refinar Meus Resultados

Tipo de Recurso 

  1. Artigos  (234)
  2. Anais de Congresso  (1)
  3. Mais opções open sub menu

Data de Publicação 

De até
Refinar
  1. Antes de1994  (7)
  2. 1994Até2003  (30)
  3. 2004Até2010  (63)
  4. 2011Até2018  (59)
  5. Após 2018  (77)
  6. Mais opções open sub menu

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.